Maureen Kimmeth
Optometrist · Washington, DCNPI 1619009693
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,500 of the $2,756 with a category attached, or 90.7%. Glaukos Corporation accounts for 91.4% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2020 at $1,570 and has fallen 95.8% since, to $67 in 2025.
Across 17 payments — averaging $162.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$3K
- E.r. Squibb & Sons, L.L.C.$93
- AbbVie$50
- Alcon$34
- Novartis$23
- Bausch & Lomb Americas Inc.$23
- plus $14 from 1 others
What the payments were for
- Consulting fees$2,50091%
- Food & beverage$2569%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 5 | $2,519 |
| E.r. Squibb & Sons, L.L.C. | 4 | $93 |
| AbbVie | 3 | $50 |
| Alcon | 2 | $34 |
| Novartis | 1 | $23 |
| Bausch & Lomb Americas Inc. | 1 | $23 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $14 |
How this compares
$2,756 in reported general payments places this provider in the 85th percentile of 71 optometrist providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyzultaLatanoprostene Bunod | 200 | $69,409 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 81 | $17,082 |
| Brimonidine Tartrate | 77 | $2,005 |
| Latanoprost | 301 | $1,130 |
| Dorzolamide Hcl | 31 | $737 |
| Timolol Maleate | 29 | $199 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Vyzulta | $23 | $69,409200 claims |
| AlconSimbrinza | $34 | $17,08281 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 71 optometrist providers in District of Columbia.
Other optometrist in Washington
- Saba MatternWashington$11K
- Evelyn DearingWashington$5K
- Gregory FoleyWashington$4K
- Nastaran GolrizWashington$4K
- Nguyen WatermanWashington$4K
- Arnold MillerWashington$3K
- Cheryl TranWashington$3K
- Thanh Loan DorsamWashington$3K
- Dalia ElkassabanyWashington$3K
- Nickey NeagleWashington$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.